Investment Thesis
Aptose Biosciences is in critical financial distress with negative stockholders' equity of -$19.4M, indicating liabilities exceed assets. The company generates zero revenue while burning $16.1M in annual operating cash flow, with only $613K in cash reserves and a current ratio of 0.53x indicating severe liquidity crisis. Continued operations appear unsustainable without significant capital infusion or strategic intervention.
APTOF Strengths
- Minimal capital expenditure ($5K) suggests focus on R&D rather than infrastructure spending
- Biotech sector positioning offers potential for transformative breakthroughs if pipeline succeeds
- No reportable long-term debt structure (though liabilities of $25.8M represent immediate concern)
APTOF Risks
- Negative stockholders' equity of -$19.4M indicates technical insolvency and high bankruptcy risk
- Zero revenue generation with -$16.1M operating cash burn rate unsustainable with only $613K cash
- Current ratio of 0.53x and quick ratio of 0.53x signal acute liquidity crisis and inability to meet short-term obligations
- Deteriorating financial position despite 50.3% improvement in net loss suggests accounting adjustments rather than operational improvement
- No insider purchases in last 90 days suggests lack of management confidence
Key Metrics to Watch
- Cash balance trend and runway (critical given monthly burn rate)
- Ability to raise capital or secure financing to extend runway
- Clinical trial progress and regulatory milestones for pipeline assets
- Liability restructuring or debt reduction initiatives
- Operating cash burn rate stabilization
APTOF Financial Metrics
APTOF Profitability Ratios
APTOF Balance Sheet & Liquidity
APTOF 5-Year Financial Trend
5-Year Trend Summary: Aptose Biosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-227.43 indicates the company is currently unprofitable.
APTOF Growth Metrics (YoY)
APTOF Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.1M | $-2.01 |
| Q2 2025 | N/A | -$7.0M | $-2.76 |
| Q1 2025 | N/A | -$5.5M | $-2.61 |
| Q3 2024 | N/A | -$7.0M | $-0.37 |
| Q2 2024 | N/A | -$7.3M | $-0.43 |
| Q1 2024 | N/A | -$9.6M | $-0.73 |
| Q3 2023 | N/A | -$9.8M | $-1.59 |
| Q2 2023 | N/A | -$10.6M | $-1.72 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
APTOF Capital Allocation
APTOF SEC Filings
Access official SEC EDGAR filings for Aptose Biosciences Inc. (CIK: 0000882361)